A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects (MIYABI PD)

January 28, 2021 updated by: Bayer

An Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Peritoneal Dialysis Subjects With Renal Anemia

The purpose of this study is to evaluate the efficacy and safety of molidustat in peritoneal dialysis subjects with renal anemia

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
51

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Japan
      • Fukui, Japan, 918-8503
        • Fukui-ken Saiseikai Hospital
      • Fukuoka, Japan, 812-8582
        • Kyushu University Hospital
      • Fukuoka, Japan, 814-0180
        • Fukuoka University Hospital
      • Fukuoka, Japan, 815-8555
        • Japanese Red Cross Fukuoka Hospital
      • Fukushima, Japan, 960-1295
        • Fukushima Medical University Hospital
      • Gifu, Japan, 500-8523
        • Asahi University Hospital
      • Kyoto, Japan, 612-8555
        • National Hospital Organization Kyoto Medical Center
      • Nara, Japan, 630-8581
        • Nara Prefecture General Medical Center
      • Niigata, Japan, 950-1197
        • Niigata City General Hospital
      • Oita, Japan, 870-0033
        • Japanese Red Cross Oita Hospital
      • Osaka, Japan, 558-8558
        • Osaka General Medical Center
    • Aichi
      • Yatomi, Aichi, Japan, 498-8502
        • Kainan Hospital
    • Ehime
      • Matsuyama, Ehime, Japan, 790-0024
        • Ehime Prefectural Central Hospital
    • Fukuoka
      • Kitakyushu, Fukuoka, Japan, 802-8555
        • Kokura Memorial Hospital
      • Kitakyushu, Fukuoka, Japan, 806-8501
        • JCHO Kyushu Hospital
      • Kurume, Fukuoka, Japan, 830-0011
        • Kurume University Hospital
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 003-0814
        • Elm Grove Clinic
    • Hyogo
      • Kobe, Hyogo, Japan, 650-0047
        • Kobe City Medical Center General Hospital
    • Kanagawa
      • Fujisawa, Kanagawa, Japan, 251-8550
        • Fujisawa City Hospital
      • Kamakura, Kanagawa, Japan, 247-8533
        • Shonan Kamakura General Hospital
      • Kawasaki, Kanagawa, Japan, 213-8587
        • Toranomon Hospital Kajigaya
      • Yokohama, Kanagawa, Japan, 227-8501
        • Showa University Fujigaoka Hospital
    • Miyagi
      • Sendai, Miyagi, Japan, 983-8512
        • Tohoku Medical And Pharmaceutical University Hospital
    • Niigata
      • Shibata, Niigata, Japan, 957-8588
        • Niigata Prefectural Shibata Hospital
    • Oita
      • Beppu, Oita, Japan, 874-0011
        • National Hospital Organization Beppu Medical Center
    • Okinawa
      • Uruma, Okinawa, Japan, 904-2293
        • Okinawa Prefectural Chubu Hospital
    • Osaka
      • Izumi, Osaka, Japan, 594-0076
        • Fuchu Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subject with end-stage kidney disease (ESKD) on peritoneal dialysis prior to assignment and not expected to start maintenance dialysis (e.g., hemodialysis, hemodiafiltration) other than peritoneal dialysis during the study period
  • Body weight > 40 and ≤ 160 kg at screening
  • Male or female subject ≥ 20 years of age at screening
  • At least one kidney

  • Subjects who meet one of the 1 or 2 following criteria

    • Subjects untreated with ESA at assignment: Mean of the last 2 Hb level (central laboratory measurement) during the screening period must be ≥ 8.0 and < 11.0 g/dL (2 measurements must be taken ≥ 2 days apart and the difference between the 2 measurements must be < 1.2 g/dL) with the last screening Hb measurement within 14 days prior to study drug assignment
    • Subjects pre treated with ESA at assignment: Mean of the last 2 Hb level (central laboratory measurement) during the screening period must be ≥ 10.0 and < 13.0 g/dL (2 measurements must be taken ≥ 2 days apart and the difference between the 2 measurements must be < 1.2 g/dL) with the last screening Hb measurement within 14 days prior to study drug assignment

  • Subjects who meet one of the 1 or 2 following criteria

    • Subjects untreated with ESA at assignment: Subject with ESKD on peritoneal dialysis for at least 2 weeks prior to assignment. AND. Subject not received ESA for 8 weeks prior to assignment. OR. In case of the patient washed out from ESAs, when mean of the last 2 Hb level (at least 2 central laboratory measurements must be taken ≥ 2 days apart) has decrease to ≥ 0.5g/dL from the Hb level (central laboratory measurement) after the last ESA administration, AND the interval from the last ESA administration to the study drug assignment should be over 2 week for epoetin-alpha/beta, 4 weeks for darbepoetin alpha or epoetin beta pegol

    • Subjects pre treated with ESA at assignment:

      • Subject with ESKD on peritoneal dialysis for at least 12 weeks prior to assignment
      • Subject treated with ESA by IV or SC within 8 weeks prior to assignment
      • Treated with 2 or 4 weekly dose of darbepoetin alfa, 4 weekly dose of epoetin beta pegol, OR 3 times per week, twice per week, weekly or bi-weekly dose of epoetin alfa/beta, and having had no more than one dose change within 8 weeks prior to assignment

Exclusion Criteria:

  • New York Heart Association (NYHA) Class III or IV congestive heart failure
  • History of cardio- (cerebro-) vascular events (e.g., unstable angina, myocardial infarction, stroke, pulmonary thromboembolism, and acute limb ischemia) within 6 months prior to randomization
  • Sustained and poorly controlled arterial hypertension (defined as systolic BP≥ 180mmHg or diastolic BP ≥ 110mmHg) or hypotension (defined as systolic BP < 90mmHg) at randomization
  • Proliferative choroidal or retinal disease, such as neovascular age-related macular degeneration or proliferative diabetic retinopathy requiring invasive treatment (e.g., intraocular injections or laser photocoagulation)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Molidustat (BAY85-3934)
Molidustat group
Drug: Molidustat (BAY85-3934)
Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Responder rate: proportion of responders among the subjects
Time Frame: Week 30 to 36

Responder is defined as meeting all of the following criteria:

(i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment
Week 30 to 36

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Rate of rise in Hb (Hemoglobin) level (g/dL/week)
Time Frame: Up to 8 weeks
Up to 8 weeks
Rate of rise in Hb (Hemoglobin) level (g/dL/week)
Time Frame: Up to 4 weeks
Up to 4 weeks
Mean Hb (Hemoglobin) level
Time Frame: Week 30 to 36
Week 30 to 36
Change in mean Hb level
Time Frame: Baseline and Week 30 to 36
Baseline and Week 30 to 36
Proportion of subjects who meet each component of the response
Time Frame: Week 30 to 36

Response:

(i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment
Week 30 to 36
Hb level
Time Frame: Baseline and Up to Week 36
Baseline and Up to Week 36
Change in Hb level
Time Frame: Baseline and Up to Week 36
Baseline and Up to Week 36
Proportion of subjects with mean hemoglobin levels are in the target range
Time Frame: Week 30 to 36
Week 30 to 36
Proportion of subjects with mean hemoglobin levels are above the target range
Time Frame: Week 30 to 36
Week 30 to 36
Proportion of subjects with mean hemoglobin levels are below the target range
Time Frame: Week 30 to 36
Week 30 to 36
Proportion of subjects with hemoglobin levels in the target range
Time Frame: Up to 36 weeks
Up to 36 weeks
Proportion of subjects with hemoglobin levels above the target range
Time Frame: Up to 36 weeks
Up to 36 weeks
Proportion of subjects with hemoglobin levels below the target range
Time Frame: Up to 36 weeks
Up to 36 weeks
Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week
Time Frame: Up to 36 weeks
Defined as change in Hb level / duration between two visits (weeks)
Up to 36 weeks
Percentage of days in the target Hb range during the evaluation period
Time Frame: Week 30 to 36
Week 30 to 36
Percentage of days in the target Hb range during the treatment period
Time Frame: Up to 36 weeks
Up to 36 weeks
Rate of rise in Hb level (g/dL/week) between each consecutive visits
Time Frame: Up to 36 weeks
Up to 36 weeks
Percentage of Hb levels in target range during the evaluation period
Time Frame: Week 30 to 36
Defined as the number of measurements in the target range / number of measurements x 100 [%])
Week 30 to 36
Percentage of Hb levels in target range during the treatment period
Time Frame: Up to 36 weeks
Defined as the number of measurements in the target range / number of measurements x 100 [%])
Up to 36 weeks
Proportion of subjects who received at least one rescue treatment
Time Frame: Up to 36 weeks
Up to 36 weeks
Proportion of subjects whose Hb level was ≥ 13.0 g/dL or < 8.0 g/dL
Time Frame: Up to 36 weeks
Up to 36 weeks
Number of participants with serious adverse events
Time Frame: Up to 36 weeks
Up to 36 weeks
Maximum concentration (Cmax) of Molidustat
Time Frame: Baseline, Week 8, Wee16 and Week 36
Baseline, Week 8, Wee16 and Week 36
Area under the concentration-time curve (AUC) of Molidustat
Time Frame: Baseline, Week 8, Wee16 and Week 36
Baseline, Week 8, Wee16 and Week 36
EPO (Erythropoietin) serum concentration of Molidustat
Time Frame: Baseline, Week 8, Wee16 and Week 36
Baseline, Week 8, Wee16 and Week 36

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bayer

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 22, 2018

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 25, 2019

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 29, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 26, 2018

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 26, 2018

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 1, 2018

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 29, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 28, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 19353

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Renal Insufficiency, Chronic

Clinical Trials on Molidustat (BAY85-3934)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings